Skip to main content
SpringerLink
Log in
Book cover

Alternative Approaches to Human Blood Resources in Clinical Practice pp 17–35Cite as

The Efficacy of Technologies to Minimise Peri-Operative Allogeneic Transfusion

  • Chapter

  • 79 Accesses

Part of the book series: Developments in Hematology and Immunology ((DIHI,volume 33))

Abstract

Concern about the side-effects of allogeneic blood transfusion, especially the transmission of viral infections, has led to the development of a variety of methods intended to minimise peri-operative transfusion. These include pharmacological agents (aprotinin, desmopressin (DDAVP), tranexamic acid (TXA), epsilon aminocaproic acid (EACA) and erythropoietin (EPO)), pre-operative autologous donation (PAD), acute normovolemic haemodilution (ANH), and intra- and post-operative cell salvage. We have performed meta-analyses of randomised trials of all of the technologies except cell salvage, using exposure to peri-operative allogeneic blood transfusion as the primary outcome [1–4]. The results are summarised here.

The International Study of Peri-operative Transfusion (ISPOT) Investigators. (Complete list of investigators and affiliations at the back of the paper). This work was carried out at the Clinical Epidemiology Unit, Loeb Research Institute, University of Ottawa, Ottawa, Canada.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Laupacis A, Fergusson D, for the International Study of Peri-operative Transfusion (ISPOT) Investigators. Drugs to minimize peri-operative blood loss in cacrdiac surgery — Meta-analyses using peri-operative blood transfusion as the outcome. Anesth Analgesia 1997;85:1258–1267.

    CAS  Google Scholar 

  2. Forgie M, Wells P, Laupacis A, Fergusson D, for the International Study of Peri-operative Transfusion (ISPOT) Investigators. Pre-operative autologous donation decreases allogeneic transfusion but increases exposure to all red cell transfusion. Arch Intern Med 1998;158:610–616.

    Article  PubMed  CAS  Google Scholar 

  3. Bryson GL, Laupacis A, Wells GA, for the International Study of Peri-operative Transfusion. Does acute normovolemic haemodilution reduce perioperative allogeneic transfusion? A meta-analysis. Anesth Analgesia 1998;86:9–15.

    CAS  Google Scholar 

  4. Laupacis A, Fergusson D, for the International Study of Peri-operative Transfusion (ISPOT) Investigators. Erythropoietin to minimize peri-operative blood transfusion. Four meta-analyses of randomized trials. Transfus Med (under review).

    Google Scholar 

  5. Fremes SE, Wong BI, Lee E, et al. Meta-analysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 1995;58:1580–1588.

    Article  Google Scholar 

  6. Cattaneo M, Harris AS, Stroberg U, Mannucci PM. The effect of desmopressin on reducing blood loss in cardiac surgery’ A meta-analysis of double-blind, placebo-controlled trials. Thromb Haem 1995;74:1064–1070.

    CAS  Google Scholar 

  7. Chalmers TC, Celano P, Sacks HS, Smith H. Bias in treatment assignment in controlled clinical trials. N Engl J Med 1983;309:1358–1361.

    Article  PubMed  CAS  Google Scholar 

  8. Schultz KF, Chalmers I, Hayes RJ, Airman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effect in controlled trials. JAMA 1995;273:408–412.

    Article  Google Scholar 

  9. Lemmer JH, Dilling EW, Morton JR, et al. Aprotinin for primary coronary artery bypass grafting: A multicenter trial of three dose regimens. Ann Thorac Surg 1996;62:1659–1668.

    Article  PubMed  Google Scholar 

  10. Jadad AR, Moore A, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Contr Clinical Trials 1996;17:1–12.

    Article  CAS  Google Scholar 

  11. Meta-Analyst.977. Lau J, Chalmers TC. 1990.

    Google Scholar 

  12. Kalangos A, Tayyareci G, Pretre R, Di Dio P, Sezerman O: Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization. Eur J Cardio-Thorac Surg 1994;8:651–656.

    Article  CAS  Google Scholar 

  13. Lemmer JH, Jr., Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994; 107:543–551.

    PubMed  Google Scholar 

  14. Bidstrup BP, Underwood SR, Sapsford RN, Streets EM. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg 1993; 105:147–152.

    PubMed  CAS  Google Scholar 

  15. Rodrigus IE, Vermeyen KM, De Hert SG, Amsel BJ, Walter PJ. Efficacy and safety of aprotinin in aortocoronary bypass and valve replacement operations: a placebo-controlled randomized double-blind study. Perfusion 1996;11;313–318.

    Article  PubMed  CAS  Google Scholar 

  16. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987;ii: 1289–1291.

    Article  Google Scholar 

  17. Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989;97:364–372.

    PubMed  CAS  Google Scholar 

  18. Fraedrich G, Weber C, Bernard C, Hettwer A, Schlosser V. Reduction of blood transfusion requirement in open heart surgery by administration of high doses of aprotinin’ preliminary results. Thorac Cardiovasc Surg 1989;37:89–91.

    Article  PubMed  CAS  Google Scholar 

  19. Locatelli A, Bertollo D, Bianchi T, et al. Aprotinin in cardiosurgery: a randomized prospective study with different protocols for use. Minerva Anestesiologica 1990; 56:973–975.

    PubMed  CAS  Google Scholar 

  20. Dietrich W, Spannagl M, Jochum M, et al. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascu-larization. Anesthesiology 1990;73:l 119–126.

    Article  Google Scholar 

  21. Boldt J, Zickmann B, Czeke A, Herold C, Dapper F, Hempelmann G. Blood conservation techniques and platelet function in cardiac surgery. Anesthesiology 1991; 75:426–432.

    Article  PubMed  CAS  Google Scholar 

  22. Gherli T, Porcu A, Padua G, et al. Reducing bleeding during extracorporeal circulation interventions by high doses of aprotinin. Minerva Cardioangiol 1992;40: 121–126.

    PubMed  CAS  Google Scholar 

  23. Deleuze P, Loisance DY, Feliz A, et al. Reduction of pre-and postoperative blood loss with aprotinin (Trasylol) during extracorporeal circulation. Arch Mal Coeur Vaiss 1991;84:1797–1802.

    PubMed  CAS  Google Scholar 

  24. Vedrinne C, Girard C, Jegaden O, et al. Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin versus autologous fresh whole blood transfusion. J Cardiothorac Vasc Anesth 1992;6:319–323.

    Article  PubMed  CAS  Google Scholar 

  25. Dietrich W, Barankay A, Hahnel C, Richter JA. High-dose aprotinin in cardiac surgery: three years′ experience in 1,784 patients. J Cardiothorac Vasc Anesth 1992; 6:324–327.

    Article  PubMed  CAS  Google Scholar 

  26. Mohr R, Goor DA, Lusky A, Lavee J. Aprotinin prevents cardiopulmonary bypass-induced platelet dysfunction. A scanning electron microscope study. Circulation 1992;86(suppl II):II405–II409.

    PubMed  CAS  Google Scholar 

  27. Cosgrove DM, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992;54:1031–1036.

    Article  PubMed  Google Scholar 

  28. Baele PL, Ruiz-Gomez J, Londot C, Sauvage M, Van Dyck MJ, Robert A. Systematic use of aprotinin in cardiac surgery: influence on total homologous exposure and hospital cost. Acta Anaesthesiologica Belgica 1992;43:103–112.

    PubMed  CAS  Google Scholar 

  29. Bailey CR, Kelleher AA, Wielogorski AK. Randomized placebo-controlled double-blind study of three aprotinin regimens in primary cardiac surgery. Br J Surg 1994; 81:969–973.

    Article  PubMed  CAS  Google Scholar 

  30. Carrera A, Martinez MV, Garcia-Guiral M, Herrero E, Peral A, Planas A. Use of high doses of aprotinin in cardiac surgery. Rev Esp Anestesiol Reanim 1994;41:13–19.

    PubMed  CAS  Google Scholar 

  31. Maccario M, Fumagalli C, Deangelis R, et al. Comparison between low and high doses of aprotinin in heart surgery. Minerva Anestesiologica 1994;60:315–320.

    PubMed  CAS  Google Scholar 

  32. Murkin JM, Lux J, Shannon NA, et al. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg 1994; 107:554–561.

    PubMed  CAS  Google Scholar 

  33. Swart MJ, Gordon PC, Hayse-Gregson PB, et al. High-dose aprotinin in cardiac surgery-a prospective, randomized study. Anaesth Intensive Care 1994; 22:529–533.

    PubMed  CAS  Google Scholar 

  34. Rocha E, Hidalgo F, Llorens R, Melero JM, Arroyo JL, Paramo JA. Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery. Circulation 1994;90:921–927.

    Article  PubMed  CAS  Google Scholar 

  35. Casas JI, Zuazu-Jausoro I, Mateo J, et al. Aprotinin versus desmopressin for patients undergoing operations with cardiopulmonary bypass. J Thorac Cardiovasc Surg 1995;110:1107–1117.

    Article  PubMed  CAS  Google Scholar 

  36. Penta de Peppo A, Danilo Pierri M, Scafuri A, et al. Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. Tex Heart Inst J 1995; 22:231–236.

    Google Scholar 

  37. Corbeau JJ, Monrigal JP, Jacob JP, et al. Comparaison des effet de l’aprotinine et de l’acide tranexamique sur le saignement en chirurgie cardiaque. Ann Fr Anesth Re-anim 1995;14:154–161.

    Article  CAS  Google Scholar 

  38. Levy JH, Pifarre R, Schaff HV, et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995; 92:2236–2244.

    Article  PubMed  CAS  Google Scholar 

  39. Lab M, Welz A, Kochs M, Mayer G, Schwandt M, Hannekum A. Aprotinin in elective primary bypass surgery: Graft patency and clinical efficacy. Eur J Cardio-thorac Surg 1995;9:206–210.

    Article  Google Scholar 

  40. Dietrich W, Dilthey G, Spannagl M, Jochum M, Braun SL, Richter JA. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite-and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. Anesthesiology 1995;83:679–689.

    Article  PubMed  CAS  Google Scholar 

  41. D’Ambra MN, Akins CW, Blackstone E, et al. Aprotinin in primary valve replacement and reconstruction: A multicenter, double-blind, placebo-controlled trial. J Thorac Cardiovasc Surg 1996;112:1081–1089.

    Article  PubMed  Google Scholar 

  42. Harder MP, Eijsman L, Roozendaal KJ, van Oeveren W, Wildevuur CRH. Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass. Ann Thorac Surg 1991;51:936–941 (abstract).

    Article  PubMed  CAS  Google Scholar 

  43. Isetta C, Gunness TK, Samat C, et al. Antifibrinolytic treatment and homologous transfusion in cardiac surgery. Eur Heart J 1993;14:424.

    Google Scholar 

  44. Liu B, Belboul A, Radberg G, et al. Effect of reduced aprotinin dosage on blood loss and use of blood products in patients undergoing cardiopulmonary bypass. Scand J Thorac Cardiovasc Surg 1993;27:149–155.

    Article  PubMed  CAS  Google Scholar 

  45. Blauhut B, Harringer W, Bettelheim P, Doran JE, Spath P, Lundsgaard-Hansen P. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994;108:1083–1091.

    PubMed  CAS  Google Scholar 

  46. Hardy JF, Desroches J, Belisle S, Perrault J, Carrier M, Robitaille D. Low-dose aprotinin infusion is not clinically useful to reduce bleeding and transfusion of homologous blood products in high-risk cardiac surgical patients. Can J Anaesth 1993;40:625–631.

    Article  PubMed  CAS  Google Scholar 

  47. Bailey CR, Wielogorski AK. Randomised placebo controlled double blind study of two low dose aprotinin regimens in cardiac surgery. Br Heart J 1994; 71:349–353.

    Article  PubMed  CAS  Google Scholar 

  48. Tabuchi N, Huet RC, Sturk A, Eijsman L, Wildevuur CR. Aprotinin preserves hae-mostasis in aspirin-treated patients undergoing cardiopulmonary bypass. Ann Thorac Surg 1994;58:1036–1039

    Article  PubMed  CAS  Google Scholar 

  49. Pugh SC, Wielogorski AK. A comparison of the effects of tranexamic acid and low-dose aprotinin on blood loss and homologous blood usage in patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth 1995;9:240–244.

    Article  PubMed  CAS  Google Scholar 

  50. Speekenbrink RG, Vonk AB, Wildevuur CR, Eijsman L. Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting. Ann Thorac Surg 1995;59:438–442.

    Article  PubMed  CAS  Google Scholar 

  51. Alvarez JM, Quiney NF, McMillan D, et al. The use of ultra-low-dose aprotinin to reduce blood loss in cardiac surgery. J Cardiothorac Vasc Anesth 1995;9:29–33.

    Article  PubMed  CAS  Google Scholar 

  52. Wendel HP, Heller W, Michel J, et al. Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage. J Thorac Cardiovasc Surg 1995; 109:1164–1172.

    Article  PubMed  CAS  Google Scholar 

  53. Bidstrup BP, Royston D, McGuinness C, Sapsford RN. Aprotinin in aspirin-pretreated patients. Perfusion 1990;5(suppl):77–81.

    Article  Google Scholar 

  54. Menichetti A, Tritapepe L, Ruvolo G, et al. Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid. J Cardiovasc Surg 1996;37:401–407.

    CAS  Google Scholar 

  55. Salzman EW, Weinstein MJ, Weintraub RM, et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial. N Engl J Med 1986;314:1402–1406.

    Article  PubMed  CAS  Google Scholar 

  56. Frankville DD, Harper GB, Lake CL, Johns RA. Hemodynamic consequences of desmopressin administration after cardiopulmonary bypass. Anesthesiology 1991; 74:988–996.

    Article  PubMed  CAS  Google Scholar 

  57. Horrow JC, Van Riper DF, Strong MD, Brodsky I, Parmet JL. Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery. Circulation 1991;84: 2063–2070.

    Article  PubMed  CAS  Google Scholar 

  58. Marquez J, Koehler S, Strelec SR, et al. Repeated dose administration of desmopressin acetate in uncomplicated cardiac surgery: a prospective, blinded, randomized study. J Cardiothorac Vasc Anesth 1992;6:674–676.

    Article  PubMed  CAS  Google Scholar 

  59. Ansell J, Klassen V, Lew R, et al. Does desmopressin acetate prophylaxis reduce blood loss after valvular heart operations? A randomized, double-blind study. J Thorac Cardiovasc Surg 1992; 104:117–123.

    PubMed  CAS  Google Scholar 

  60. Gratz I, Koehler J, Olsen D, et al. The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations. J Thorac Cardiovasc Surg 1992; 104:1417–1422.

    PubMed  CAS  Google Scholar 

  61. Dilthey G, Dietrich W, Spannagl M, Richter JA. Influence of desmopressin acetate on homologous blood requirements in cardiac surgical patients pretreated with aspirin. J Cardiothorac Vasc Anesth 1993;7:425–430.

    Article  PubMed  CAS  Google Scholar 

  62. Sheridan DP, Card RT, Pinilla JC, et al. Use of desmopressin acetate to reduce blood transfusion requirements during cardiac surgery in patients with acetylsalicylic-acid-induced platelet dysfunction. Can J Surg 1994;37:33–36.

    PubMed  CAS  Google Scholar 

  63. Temeck BK, Bachenheimer LC, Katz NM, Coughlin SS, Wallace RB. Desmopressin acetate in cardiac surgery: a double-blind, randomized study. South Med J 1994; 87:611–615.

    Article  PubMed  CAS  Google Scholar 

  64. Spyt TJ, Weerasena NA, Bain WH, Lowe GDO, Rumley A. The effects of desmopressin acetate (DDAVP) on haemostasis and blood loss in routine coronary artery bypass surgery: a randomized, double-blind trial. Perfusion 1990;(suppl):57–61.

    Google Scholar 

  65. Horrow JC, Van Riper DF, Strong MD, Grunewald KE, Parmet JL. The dose-response relationship of tranexamic acid. Anesthesiology 1995;82:3 83–92.

    Google Scholar 

  66. Coffey A, Pittmam J, Halbrook H, Fehrenbacher J, Beckman D, Hormuth D. The use of tranexamic acid to reduce postoperative bleeding following cardiac surgery: a double-blind randomized trial. Am Surg 1995;61:566–568.

    PubMed  CAS  Google Scholar 

  67. Katsaros D, Petricevic M, Snow NJ, Woodhall DD, Van Bergen R. Tranexamic acid reduces postbypass blood use: A double-blind, prospective, randomized study of 210 patients. Ann Thorac Surg 1996;61:1131–1135.

    Article  PubMed  CAS  Google Scholar 

  68. Shore-Lesserson L, Reich DL, Vela-Cantos F, Ammar T, Ergin MA. Tranexamic acid reduces transfusions and mediastinal drainage in repeat cardiac surgery. Anesth Analgesia 1996;83:18–26.

    CAS  Google Scholar 

  69. Daily PO, Lamphere JA, Dembitsky WP, Adamson RM, Dans NF. Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting. A randomized, prospective, double-blind study. J Thorac Cardiovasc Surg 1994;108:99–106.

    PubMed  CAS  Google Scholar 

  70. Goodnough LT, Rudnick S, Price TH, et al. Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med 1989;321:1163–1168

    Article  PubMed  CAS  Google Scholar 

  71. Bormann B von, Weidler B, Friedrich M, von Andrian-Werburg H. Recombinant erythropoietin in autologous blood donation. Anaesthesist 1991;40:386–390

    Google Scholar 

  72. Mercuriali F, Zanella A, Barosi G, et al. Use of erythropoietin to increase the volume of autologous blood donated by orthopedic patients. Transfusion; 1993;33:55–60

    Article  PubMed  CAS  Google Scholar 

  73. Biesma DH, Kraaijenhagen RJ, Marx JJ, van de Wiel A. The efficacy of subcutaneous recombinant human erythropoietin in the correction of phlebotomy-induced anemia in autologous blood donors. Transfusion 1993;33:825–829

    Article  PubMed  CAS  Google Scholar 

  74. Beris P, Mermillod B, Levy G, et al Recombinant human erythropoietin as adjuvant treatment for autologous blood donation. A prospective study. Vox Sang 1993;65: 212–218

    Article  PubMed  CAS  Google Scholar 

  75. Goodnough LT, Price TH, Friedman KD, et al. A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: dose, response, toxicity, and efficacy. Transfusion 1994;34:66–71

    Article  PubMed  CAS  Google Scholar 

  76. Biesma DH, Marx JJM, Kraaijenhagen RJ, Franle W, Messinger D, van de Wiel A. Lower homologous blood requirement in autologous blood donors after treatment with recombinant human erythropoietin. Lancet 1994;344:367–370

    Article  PubMed  CAS  Google Scholar 

  77. Schlaeppi B, Gunter P, Nydegger UE. Enhancing the efficacy of preoperative autologous blood donation by erythropoietin. Transf Sci 1994; 15:171–177

    Article  CAS  Google Scholar 

  78. Yuen K, Matthews JP. Recombinant human erythropoietin (R-HuEPO) and autologous donation. Document from Janssen Cilag Limited 1995.

    Google Scholar 

  79. Price TH, Goodnough LT, Vogler WR, et al. The effect of recombinant human erythropoietin on the efficacy of autologous blood donation in patients with low hemato-crits — a multicenter, randomized, double-blind, controlled trial. Transfusion 1996; 36:29–36

    Article  PubMed  CAS  Google Scholar 

  80. Tryba M, Kindler D, Schulte-Tamburen A. Preoperative use of low dose human erythropoietin in combination with parenteral iron substitution for the stimulation of autologous blood donation in patients before elective orthopaedic surgical interventions. The role of epoetin alpha in surgery. Forging the link in blood conservation. Published by Adelphi Communications, UK 1995; 6–7.

    Google Scholar 

  81. Watanabe Y, Fuse K, Naruse Y, et al. Subcutaneous use of erythropoietin in heart surgery. Ann Thorac Surg 1992;54:479–483

    Article  PubMed  CAS  Google Scholar 

  82. Kulier AH, Gombotz H, Fuchs G, Vuckovic U, Metzler H. Subcutaneous recombinant human erythropoietin and autologous blood donation before coronary artery bypass surgery. Anesth Analg 1993;76:102–106

    Article  PubMed  CAS  Google Scholar 

  83. Schmoeckel M, Nollert G, Mempel M, Mempel W, Reichart B. Effects of recombinant human erythropoietin on autologous blood donation before open heart surgery. Thorac Cardiovasc Surg. 1993;41:364–368

    Article  PubMed  CAS  Google Scholar 

  84. Hayashi J, Kumon K, Takanashi S, et al. Subcutaneous administration of recombinant human erythropoietin before cardiac surgery: a double-blind, multicenter trial in Japan. Transfusion 1994;34:142–146

    Article  PubMed  CAS  Google Scholar 

  85. Walpoth BH, Galliker B, Spirig P, Haeberli A, Rosenmund A, Althaus U, Nydegger UE. Use of epoetin alpha in autologous blood donation programs for patients scheduled for elective cardiac surgery. Sem Hematol 1996;22(suppl 2);75–76.

    Google Scholar 

  86. Canadian Orthopedic Perioperative Erythropoietin Study Group. Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Lancet 1993;341:1227–1232

    Google Scholar 

  87. De Andrade JR, Jove M, Landon G, Frei D, Guitfoyle M, Young D. Baseline hemoglobin as a predictor of risk of transfusion and response to epoetin alfa in orthopedic surgery patients. J Bone Joint Surg Am 1966;78-A:62–72.

    Google Scholar 

  88. Faris PM, Ritter MA, Abels RI, American Erythropoietin Study Group. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation. J Bone Joint Surg 1996;78-A:62–72

    Google Scholar 

  89. D’Ambra MN, Lynch KE, Boccagno MS, Vlahakes GJ. The effect of perioperative administration of recombinant human erythropoietin (r-HuEPO) in CABG patients: a double blind, placebo-controlled study. Anesthesiology 1992;77:A159

    Article  Google Scholar 

  90. Sowade O, Warnke H, Scigalla P, et al. Avoidance of allogeneic blood transfusions by treatment with Epoetin Beta (Recombinant Human Erythropoietin) in patients undergoing open-heart surgery. Blood. 1997;89:411–418

    PubMed  CAS  Google Scholar 

  91. Elawad AR, Jonsson S, Laurell M, Fredin HO. Predonation autologous blood in hip arthroplasty. Acta Orthop Scand 1991; 62:218–222.

    Article  PubMed  CAS  Google Scholar 

  92. Lorentz A, Osswald PM, Schilling M, Jani L. A comparison of autologous transfusion procedures in hip surgery. Anaesthesist 1991;40:205–213.

    PubMed  CAS  Google Scholar 

  93. Hoynck van Papendrecht MA, Hop W, Langenhorst BL, Kothe FC, Marquet RL, Jeekel J. Feasibility of a predeposit autologous blood donation program in colorectal cancer patients: results from a randomized clinical study. Vox Sang 1992;62:102–107.

    Article  Google Scholar 

  94. Heiss MM, Mempel W, Jauch KW, et al. Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery. Lancet 1993; 342: 1328–1333.

    Article  PubMed  CAS  Google Scholar 

  95. Busch OR, Hop WC, Hoynck van Papendrecht MA, Marquet RL, Jeekel J. Blood transfusions and prognosis in colorectal cancer. N Engl J Med 1993; 328:1372–1376.

    Article  PubMed  CAS  Google Scholar 

  96. Kajikawa M, Nonami T, Kurokawa T, et al. Autologous blood transfusion for hepa-tectomy in patients with cirrhosis and hepatocellular carcinoma: use of recombinant human erythropoietin. Surgery 1994; 115:727–734.

    PubMed  CAS  Google Scholar 

  97. Hallowell P. Transfusion of fresh autologous blood in open-heart surgery. A method for reducing blood bank requirements. J Thorac Cardiovasc Surg 1972;64:941–948.

    PubMed  CAS  Google Scholar 

  98. Dietrich W, Barankay A, Dilthey G, et al. Reduction of blood utilization during myocardial revascularization. J Thorac Cardiovasc Surg 1989;97:213–219.

    PubMed  CAS  Google Scholar 

  99. Boldt J, Kling D, Weidler B, et al. Acute preoperative hemodilution in cardiac surgery: volume replacement with a hypertonic saline-hydroxyethyl starch solution. J Cardiothorac Vasc Anesth 1991;5:23–28.

    Article  PubMed  CAS  Google Scholar 

  100. Vedrinne C, Girard C, Jegaden O, et al. Reduction in blood loss and blood use after cardiopulmonary bypaass with high-dose aprotinin versus autologous fresh whole blood transfusion. J Cardiothorac Vasc Anesth 1992;6:319–323.

    Article  PubMed  CAS  Google Scholar 

  101. Herregods L, Foubert L, Moerman A, et al. Comparative study of limited normo-volaemic haemodilution in patients with left main coronary artery stenosis. Anaesthesia 1995;50:950–953.

    Article  PubMed  CAS  Google Scholar 

  102. Triulzi DJ, Gilmor GD, Ness PM, et al. Efficacy of autologous fresh whole blood or platelet-rich plasma in adult cardiac surgery. Transfusion 1995;35:627–634.

    Article  PubMed  CAS  Google Scholar 

  103. Lorentz A, Osswald PM, Schilling M, Jani L. A comparison of autologous transfusion procedures in hip surgery. Anaesthesist 1991;40:205–213.

    PubMed  CAS  Google Scholar 

  104. Vara Thorbeck R, Rosell Pradas J, Mekinassi KL, et al. Prevention of thromboembolic disease and post-transfusional complications using normovolemic hemodilution in arthroplasty surgery of the hip. Rev Chir Orthop Réparatrice Appar Mot 1990;76:267–271.

    Google Scholar 

  105. Bennett SR. Perioperative autologous blood transfusion in elective total hip prosthesis operations. Ann R Coll Surg Eng 1994;76:95–98.

    CAS  Google Scholar 

  106. Rose D, Coutsoftides T. Intraoperative normovolemic hemodilution. J Surg Res 1981;31:375–381.

    Article  PubMed  CAS  Google Scholar 

  107. Moyes DG, Mistry BD, Conlan AA. Normovolaemic haemodilution using dextran 70 in thoracic surgery. S Afr Med J 1985;67:762–764.

    PubMed  CAS  Google Scholar 

  108. von Bormann B, Weidler B, Boldt J, et al. Acute normovolemic hemodilution in extensive surgical interventions. Chirurg 1986;57:457–464.

    Google Scholar 

  109. Bonnet MC, Julia JM, Mathieu-Daude JC, du Cailar J. Value of hemodilution in maxillofacial surgery for postoperative traumatic edema and graft viability. Ann Fr Anesth Reanim 1986;5:243–284.

    Article  PubMed  CAS  Google Scholar 

  110. Malinovsky JM, Bouyer L, Rusterholtz T, et al. Saving of blood products by normovolemic hemodilution in prostate resection. Ann Fr Anesth Reanim 1989;8(suppl):R120.

    PubMed  Google Scholar 

  111. Atallah MM, Abdelbaky SM, Saied MM. Does timing of hemodilution influence the stress response and overall outcome? Anesth Analg 1993;76:113–117.

    Article  PubMed  CAS  Google Scholar 

  112. EPREX (epoetin alpha) product monograph, Janssen-Ortho Inc, Canada, 1996

    Google Scholar 

  113. Kanter MH, van Maanen D, Anders KH et al. Preoperative autologous blood donations before elective hysterectomy. JAMA 1996; 276:798–801.

    Article  PubMed  CAS  Google Scholar 

  114. Linden JV, Kaplan HS. Transfusion errors: causes and effects. Transf Med Rev 1994;8:169–183.

    Article  CAS  Google Scholar 

  115. Linden JV, Paul B, Dressler KP. A report of 104 transfusion errors in New York State. Transfusion 1992;32:601–606.

    Article  PubMed  CAS  Google Scholar 

  116. LeLorier J, Grégoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997;337:536–542.

    Article  PubMed  CAS  Google Scholar 

  117. Lemmer JH Jr. Reporting the results of blood conservation studies: The need for uniform and comprehensive methods. Ann Thorac Surg 1994;58:1305–1306.

    Article  PubMed  Google Scholar 

Download references

Authors
  1. A. Laupacis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Fergusson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Red Cross Blood Bank Noord Nederland, The Netherlands

    C. Th. Smit Sibinga  & P. C. Das  & 

  2. C.L. Mclntosh & Ass., Rockville, MD, USA

    J. C. Fratantoni

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Laupacis, A., Fergusson, D. (1998). The Efficacy of Technologies to Minimise Peri-Operative Allogeneic Transfusion. In: Sibinga, C.T.S., Das, P.C., Fratantoni, J.C. (eds) Alternative Approaches to Human Blood Resources in Clinical Practice. Developments in Hematology and Immunology, vol 33. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5619-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5619-0_3

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7571-5

  • Online ISBN: 978-1-4615-5619-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation